Latest healthtech and biotech deals
The largest from last week:
🇺🇸 Elemy, a SF-based B2B2C platform for paediatric behavioural care, raised $219M at a $1.2B valuation. The company launched a little more than a year ago, and it's already an unicorn. As of today, there are 18 mental health unicorns, of which 12 reached unicorn status in 2021 alone.
🇮🇳 Online pharmacy PharmEasy raised $350M. The company is now valued at $5.6 billion, and it is planning an IPO by March 2022.
🇺🇸 CinCor Pharma, a clinical-stage biopharmaceutical developing next-generation treatments for cardio-renal diseases, raised $143 million Series B.
🇺🇸 Lark Health, an artificial intelligence-enabled platform that helps users to manage chronic conditions, raised $100 million Series D. The startup will use the new funds to grow the platform’s virtual care integrations with payers.
Other promising deals from around the globe:
🇺🇸 Lively, a SF-based health savings account (HSA) startup, raised $80M to continue helping Americans save for healthcare and retirement. According to Devenir, HSA assets growth has remained strong despite the pandemic, "increasing to $73.5 billion in assets held in over 29 million accounts, a year-over-year increase of 19% for assets."
🇨🇭 SkyCell, a Zug-based company developing data-driven container solutions, raised $35M Series C. These smart shock-absorbing containers allow pharma companies to optimise their supply chain by not only transporting medicines and vaccines but also by reducing and predicting the risk of delivering temperature-sensitive drugs.
🇺🇸 Oshi Health, a NYC-based virtual-first gastrointestinal care platform, raised $23M Series A. The startup offers an evidence-based, whole-person care protocol to diagnose and treat patients with gastrointestinal conditions.
🇩🇪 Telepharmacy platform MAYD delivering meds within 30 minutes from a local pharmacy in Berlin, raised $15M Seed round. The Berlin-based startup works with selected pharmacies, which receive and pick the orders but is MAYD who provides the fleet of drivers who take care of the delivery. Regulatory restrictions and fragmentation across the different health systems in Europe, e.g. limitations on e-prescriptions, is one of the reasons why an on-demand model in healthcare has been slow to adopt (MAYD co-founder Lukas Pieczonka, Techcrunch).
Read up on all the latest health deals in Dealroom.co